Intellia
Intellia Therapeutics Doses First Patient in Phase III Hereditary Angioedema Trial of CRISPR Drug
The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.
The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and transthyretin amyloidosis.
Intellia Cuts AATD Gene Insertion Program, 27 Percent of Workforce in Strategic Reorganization
These moves will enable the gene-editing company to focus resources on late-stage programs as it aims to launch a commercial product by 2027, it said.
The FDA approved three new gene therapy products in 2024 and expanded indications for two others, all for rare diseases.
Intellia Starts Phase III Hereditary Angioedema Trial for CRISPR Gene-Editing Therapy
In the HAELO trial, the firm will randomize 60 HAE patients to NTLA-2002 or placebo and compare the number of inflammatory attacks.
Sep 17, 2024